Cost‐Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke
Zhou LW, Kraler L, de Havenon A, Lansberg MG. Cost‐Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke. Journal Of The American Heart Association 2022, 11: e024992. PMID: 35656996, PMCID: PMC9238703, DOI: 10.1161/jaha.121.024992.Peer-Reviewed Original ResearchMeSH KeywordsAspirinCilostazolClopidogrelCost-Benefit AnalysisHumansMarkov ChainsPlatelet Aggregation InhibitorsQuality-Adjusted Life YearsSecondary PreventionStrokeTiclopidineConceptsQuality-adjusted life yearsHealth care costsHigher quality-adjusted life yearsNet monetary benefitLifetime quality-adjusted life yearsProbabilistic sensitivity analysesCare costsMonetary benefitsSensitivity analysisLife yearsCost inputsLifetime costsLower health care costsCost savingsCostBest available dataWillingnessSavingsMonte Carlo simulationsTreatment effectsCarlo simulationsAvailable dataBenefitsDecision tree